Drug Profile
BCD 600
Alternative Names: BCD-600Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator BIOCND
- Developer Pharma Research BIO
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Stomatitis
Highest Development Phases
- No development reported Stomatitis
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Stomatitis in South Korea
- 16 Dec 2016 BCD 600 is available for licensing as of 16 Dec 2016. http://www.biocnd.com/eng/research/research_010100.html
- 16 Dec 2016 Preclinical trials in Stomatitis in South Korea (unspecified route)